WallStSmart

Merck & Company Inc (MRK)vsSensus Healthcare Inc (SRTS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 239213% more annual revenue ($65.77B vs $27.48M). MRK leads profitability with a 13.6% profit margin vs -28.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

SRTS

Hold

35

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 4.7Quality: 8.5
Piotroski: 3/9Altman Z: 6.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-48.8%)

Margin of Safety

-48.8%

Fair Value

$80.79

Current Price

$118.72

$37.93 premium

UndervaluedFair: $80.79Overvalued
SRTSOvervalued (-6.3%)

Margin of Safety

-6.3%

Fair Value

$4.48

Current Price

$3.09

$1.39 premium

UndervaluedFair: $4.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$280.20B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

SRTS4 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

EPS GrowthGrowth
433.3%10/10

Earnings expanding 433.3% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.8010/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.0x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SRTS4 concerns · Avg: 2.5/10
Market CapQuality
$46.92M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-17.1%2/10

ROE of -17.1% — below average capital efficiency

Revenue GrowthGrowth
-62.2%2/10

Revenue declined 62.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SRTS

The strongest argument for SRTS centers on Price/Book, EPS Growth, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : SRTS

The primary concerns for SRTS are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while SRTS is a turnaround play — different risk/reward profiles.

SRTS carries more volatility with a beta of 1.19 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 35/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Sensus Healthcare Inc

HEALTHCARE · MEDICAL DEVICES · USA

Sensus Healthcare, Inc. manufactures, distributes and markets superficial radiation therapy devices to healthcare providers worldwide. The company is headquartered in Boca Raton, Florida.

Want to dig deeper into these stocks?